Glioblastoma--more questions than answers?
Reardon
David A
DA
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. reard003@mc.duke.edu
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis; D002330:Carmustine / Q000008:administration & dosage; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000628:therapy; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003652:Decanoic Acids / Q000008:administration & dosage; D005909:Glioblastoma / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D011091:Polyesters / Q000008:administration & dosage; D015398:Signal Transduction; D000077204:Temozolomide
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003652:Decanoic Acids; D011091:Polyesters; D003606:Dacarbazine; C055401:decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; D002330:Carmustine; D000077204:Temozolomide